Research Topics
| Steven J FeigenbergSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapySteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 62:397-405. 2005..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...- Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 62:956-64. 2005..To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate cancer... - A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancerSteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Am J Clin Oncol 29:458-62. 2006..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome... - What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?Steven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 61:1003-10. 2005..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era... - A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancerSteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Thorac Oncol 2:287-92. 2007..To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic radiotherapy (TRT) for completely resected stage II and IIIA non-small cell lung cancer... - Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluationSteven J Feigenberg
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
J Appl Clin Med Phys 8:2268. 2007..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system... - A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implantThomas N Eade
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
Int J Radiat Oncol Biol Phys 71:338-45. 2008..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer... - Increased recurrences using intensity-modulated radiation therapy in the postoperative settingAruna Turaka
Departments of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Am J Clin Oncol 33:599-603. 2010..To determine the pattern of failures following intensity modulated radiation therapy for head and neck cancer... - Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancerMark K Buyyounouski
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 63:1455-62. 2005..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer... - The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancerAlexandra L Hanlon
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 67:1082-7. 2007..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer... - Radiation therapy for angiosarcomaJon R Ward
Department of Radiation Oncology, University of Florida Health Science Center, 2000 SW Archer Rd, Gainesville, Florida 32608, USA
Head Neck 25:873-8. 2003..Patients should be treated aggressively with surgical resection and preoperative or postoperative radiation therapy... - Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with combined-modality therapy: the importance of radiation field selectionDaniel T Chang
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610 0385, USA
Int J Radiat Oncol Biol Phys 67:1043-51. 2007..To determine the long-term outcome of a consistent treatment approach with electron beam postmastectomy radiation therapy (PMRT) in breast cancer patients with > or =10 positive nodes treated with combined-modality therapy... - Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?Stephen F Andrews
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 104:299-304. 2005..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes... - Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trialAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Int J Radiat Oncol Biol Phys 64:518-26. 2006..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial... - Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancerAruna Turaka
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Int J Radiat Oncol Biol Phys 79:65-70. 2011..To determine differences in clinical outcomes using intensity-modulated radiotherapy (IMRT) or a standard low neck field (LNF) to treat low neck... - A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapyDerek B Chism
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
Int J Radiat Oncol Biol Phys 59:380-5. 2004..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach... - Angiosarcoma after breast-conserving therapyAlan T Monroe
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA
Cancer 97:1832-40. 2003..The aggressive nature of this disease demands further investigation of adjuvant therapy to prevent recurrence of disease after surgery... - Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using electronsSteven J Feigenberg
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA
Int J Radiat Oncol Biol Phys 56:716-25. 2003..CONCLUSION: Findings include a low rate of clinically detectable locoregional recurrence. The data suggest benefits for the addition of full axillary RT in node-positive patients and chest wall RT in patients with T2N0 disease... - Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studiesNoel M Kramer
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111-2497, USA
Head Neck 27:406-14. 2005..Only sites of disease recurrence need to be covered in the reirradiation fields... - Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case reportDavid J D'Ambrosio
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
J Neurooncol 85:77-9. 2007..Prophylactic cranial irradiation (PCI) is commonly offered to patients with limited stage primary small cell lung cancer following a complete response... - Prostate cancer radiotherapy dose response: an update of the fox chase experienceAlan Pollack
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Urol 171:1132-6. 2004.... - Rectal dose variation during the course of image-guided radiation therapy of prostate cancerLili Chen
Radiation Oncology Department, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Radiother Oncol 95:198-202. 2010..To investigate the change in rectal dose during the treatment course for intensity-modulated radiotherapy (IMRT) of prostate cancer with image-guidance... - Prostate cancer risk assessment program: a 10-year update of cancer detectionVeda N Giri
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19012, USA
J Urol 178:1920-4; discussion 1924. 2007..Guidelines for screening men at high risk for prostate cancer remain under investigation. We report our 10-year cancer detection data from the Prostate Cancer Risk Assessment Program, a longitudinal screening program for men at high risk... - Oligodendroglioma: does deferring treatment compromise outcome?Steven J Feigenberg
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA
Am J Clin Oncol 26:e60-6. 2003.... - Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastasesKyle E Rusthoven
University of Colorado Denver, Department of Radiation Oncology, Pathology, and Medical Oncology, Aurora, CO 80045, USA
J Clin Oncol 27:1572-8. 2009..To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three hepatic metastases... - Celecoxib to decrease urinary retention associated with prostate brachytherapySteven J Feigenberg
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
Brachytherapy 2:103-7. 2003..CONCLUSIONS: The use of celecoxib appears to result in decreased urinary retention following prostate brachytherapy... - Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: case reportEdwina L Berman
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Neurosurgery 61:E1099; discussion E1099. 2007..To present a rare case of a radiation-induced malignancy after stereotactic radiosurgery... - Accelerated partial breast irradiation via brachytherapy: A patterns-of-care analysis with ASTRO consensus statement groupingsZain A Husain
Department of Radiation Oncology, University of Maryland Medical System, Baltimore, MD
Brachytherapy 10:479-85. 2011..We performed a patterns-of-care analysis for patients undergoing breast brachytherapy and compared these results with the American Society for Radiation Oncology (ASTRO) consensus statement... - Radiosurgery for paraganglioma of the temporal boneSteven J Feigenberg
Department of Radiation Oncology, University of Florida Health Science Center, PO Box 100385, Gainesville, FL 32610-0385, USA
Head Neck 24:384-9. 2002..CONCLUSIONS: In this series, the results with stereotactic radiosurgery are discouraging compared with our results with conventional fractionated radiotherapy in patients with paraganglioma of the temporal bone... - Angiosarcoma after breast-conserving therapy: experience with hyperfractionated radiotherapySteven J Feigenberg
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610-0385, USA
Int J Radiat Oncol Biol Phys 52:620-6. 2002..For previously untreated angiosarcoma, we now recommend hyperfractionated RT followed by surgery to enhance disease control and remove as much reirradiated tissue as possible... - Non-small cell lung cancerDavid S Ettinger
J Natl Compr Canc Netw 6:228-69. 2008 - In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046Mark K Buyyounouski
Int J Radiat Oncol Biol Phys 60:1664-5; author reply 1666. 2004 - Androgen suppression plus radiation therapy for prostate cancerEric M Horwitz
JAMA 292:2084-5; author reply 2085. 2004 - Intensity-modulated radiotherapy for early larynx cancer: is there a role?Steven J Feigenberg
Int J Radiat Oncol Biol Phys 68:2-3. 2007 - Non-small cell lung cancer clinical practice guidelines in oncologyDavid S Ettinger
J Natl Compr Canc Netw 4:548-82. 2006